Induction and activation of human Th17 by targeting antigens to dendritic cells via dectin-1.
Dorothée Duluc, HyeMee Joo, Ling Ni, Wenjie Yin, Katherine Upchurch, Dapeng Li, Yaming Xue, Peter Klucar, Sandra Zurawski, Gerard Zurawski, SangKon Oh
Index: J. Immunol. 192(12) , 5776-88, (2014)
Full Text: HTML
Abstract
Recent compelling evidence indicates that Th17 confer host immunity against a variety of microbes, including extracellular and intracellular pathogens. Therefore, understanding mechanisms for the induction and activation of Ag-specific Th17 is important for the rational design of vaccines against pathogens. To study this, we employed an in vitro system in which influenza hemagglutinin (HA) 1 was delivered to dendritic cells (DCs) via Dectin-1 using anti-human Dectin-1 (hDectin-1)-HA1 recombinant fusion proteins. We found that healthy individuals maintained broad ranges of HA1-specific memory Th17 that were efficiently activated by DCs targeted with anti-hDectin-1-HA1. Nonetheless, these DCs were not able to induce a significant level of HA1-specific Th17 responses even in the presence of the Th17-promoting cytokines IL-1β and IL-6. We further found that the induction of surface IL-1R1 expression by signals via TCRs and common γ-chain receptors was essential for naive CD4(+) T cell differentiation into HA1-specific Th17. This process was dependent on MyD88, but not IL-1R-associated kinase 1/4. Thus, interruptions in STAT3 or MyD88 signaling led to substantially diminished HA1-specific Th17 induction. Taken together, the de novo generation of pathogen-specific human Th17 requires complex, but complementary, actions of multiple signals. Data from this study will help us design a new and effective vaccine strategy that can promote Th17-mediated immunity against microbial pathogens. Copyright © 2014 by The American Association of Immunologists, Inc.
Related Compounds
Related Articles:
MHC class II presentation is controlled by the lysosomal small GTPase, Arl8b.
2015-03-01
[J. Immunol. 194(5) , 2079-88, (2015)]
2015-03-01
[Tissue Eng. Part A 21(5-6) , 948-59, (2015)]
2015-03-01
[J. Neurooncol. 122(1) , 21-33, (2015)]
2014-08-15
[J. Immunol. 193(4) , 1717-27, (2014)]
2015-02-01
[J. Clin. Invest. 125(2) , 752-68, (2015)]